slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 47,311-47,340
Pages 3,679
Rows per page 30
Component
47,311-47,340 of 110,355
190
The slide uses a 'show, don't tell' approach by presenting the actual questionnaire items to demonstrate their inherent subjectivity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
191
The slide uses direct quotes from investigators to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
192
The slide uses a Q&A format to present expert testimony regarding trial unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
193
The slide serves as a summary of deeper investigative findings regarding clinical trial data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
194
Focuses on trial design bias and potential data suppression.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
196
Includes chemical structures of Diazoxide and Choline to illustrate the 'salt' formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
197
Includes screenshots of FDA Orange Book data and the front page of US Patent 7,572,789.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
198
The slide lists four specific US patents to support the claim of weakness.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
199
The slide uses a red arrow to point from the summary list to the specific boxed text in the FDA label excerpt.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
200
The slide serves as a product landscape overview to contrast current market offerings with the subject drug (Vykat).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
201
The slide uses a 'before-after' or 'comparison' logic to undermine the pricing power of the target company (Vykat) by highlighting readily available, cheaper alternatives.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
202
The slide uses a 'zoom-in' callout technique to highlight a specific claim in a scientific poster and then critiques the lack of supporting evidence for that claim.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
204
The slide uses a forensic approach to discredit clinical data, specifically targeting the validity of a poster presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
205
The slide uses annotated charts to highlight alleged data manipulation in a clinical study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
206
The slide uses a visual callout (yellow box) to highlight the specific data column in the table that contradicts the plotted graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
207
The slide presents a Q&A transcript excerpt highlighting potential fraud and competitive threats.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
208
The slide uses a line chart to visually debunk a competitor's claim about drug absorption kinetics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
209
Uses a pharmacokinetic chart to illustrate the mechanism of XR vs immediate release to debunk the necessity of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
210
The slide uses two charts to illustrate why XR is ineffective for this specific drug profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
211
The slide uses a table to contrast the solubility of different diazoxide forms to undermine the company's rationale for their specific formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
212
The slide uses a combination of a simulated PK model and a clinical study figure to challenge the necessity and efficacy of the DCCR tablet.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
213
The slide uses a 'claim-refutation' structure to dismantle the target company's product differentiation narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
214
The slide uses molecular weight calculations to expose that DCCR is simply a salt form of diazoxide, implying the price premium is unjustified.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
215
The slide uses a Q&A format to validate the thesis that MDCalc is a key driver for off-label drug substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
216
Uses direct quotes from interviews to undermine the value proposition of the target company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
217
Uses expert quotes to debunk the necessity of the company's proprietary drug formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
218
Uses FDA label excerpts to highlight the contradiction between the drug's design and its actual usage/safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
219
The slide uses Q&A transcripts to highlight internal knowledge of safety risks and potential for generic substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
220
The slide uses a quote from a trial investigator to expose a potential safety oversight in study design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
221
The slide uses a Q&A transcript format to build a case against the drug's physical formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit